AIM: To review the recent evolution of spine SBRT with emphasis on single dose treatments. BACKGROUND: Radiation treatment of spine metastases represents a challenging problem in clinical oncology, because of the high risk of inflicting damage to the spinal cord. While conventional fractionated radiation therapy still constitutes the most commonly used modality for palliative treatment, notwithstanding its efficacy in terms of palliation of pain, local tumor control has been approximately 60%. This limited effectiveness is due to previous lack of technology to precisely target the tumor while avoiding the radiosensitive spinal cord, which constitutes a dose-limiting barrier to tumor cure. MATERIALS AND METHODS: A thorough review of the available literature on spine SBRT has been carried out and critically assessed. RESULTS: Stereotactic body radiotherapy (SBRT) emerges as an alternative, non-invasive high-precision approach, which allows escalation of tumor dose, while effectively sparing adjacent uninvolved organs at risk. Engaging technological advances, such as on-line Cone Beam Computed Tomography (CBCT), coupled with Dynamic Multi-Leaf Collimation (DMLC) and rapid intensity-modulated (IMRT) beam delivery, have promoted an interactive image-guided (IGRT) approach that precisely conforms treatment onto a defined target volume with a rapid dose fall-off to collateral non-target tissues, such as the spinal cord. Recent technological developments allow the use of the high-dose per fraction mode of hypofractionated SBRT for spinal oligometastatic cancer, even if only a few millimeters away from the tumor. CONCLUSION: Single-dose spine SBRT, now increasingly implemented, yields unprecedented outcomes of local tumor ablation and safety, provided that advanced technology is employed.
AIM: To review the recent evolution of spine SBRT with emphasis on single dose treatments. BACKGROUND: Radiation treatment of spine metastases represents a challenging problem in clinical oncology, because of the high risk of inflicting damage to the spinal cord. While conventional fractionated radiation therapy still constitutes the most commonly used modality for palliative treatment, notwithstanding its efficacy in terms of palliation of pain, local tumor control has been approximately 60%. This limited effectiveness is due to previous lack of technology to precisely target the tumor while avoiding the radiosensitive spinal cord, which constitutes a dose-limiting barrier to tumor cure. MATERIALS AND METHODS: A thorough review of the available literature on spine SBRT has been carried out and critically assessed. RESULTS: Stereotactic body radiotherapy (SBRT) emerges as an alternative, non-invasive high-precision approach, which allows escalation of tumor dose, while effectively sparing adjacent uninvolved organs at risk. Engaging technological advances, such as on-line Cone Beam Computed Tomography (CBCT), coupled with Dynamic Multi-Leaf Collimation (DMLC) and rapid intensity-modulated (IMRT) beam delivery, have promoted an interactive image-guided (IGRT) approach that precisely conforms treatment onto a defined target volume with a rapid dose fall-off to collateral non-target tissues, such as the spinal cord. Recent technological developments allow the use of the high-dose per fraction mode of hypofractionated SBRT for spinal oligometastatic cancer, even if only a few millimeters away from the tumor. CONCLUSION: Single-dose spine SBRT, now increasingly implemented, yields unprecedented outcomes of local tumor ablation and safety, provided that advanced technology is employed.
Authors: Amit K Garg; Almon S Shiu; James Yang; Xin-Shelley Wang; Pamela Allen; Barry W Brown; Patricia Grossman; Erik K Frija; Mary Frances McAleer; Syed Azeem; Paul D Brown; Laurence D Rhines; Eric L Chang Journal: Cancer Date: 2012-04-17 Impact factor: 6.860
Authors: Samuel Ryu; Jian-Yue Jin; Ryan Jin; Jack Rock; Munther Ajlouni; Benjamin Movsas; Mark Rosenblum; Jae Ho Kim Journal: Cancer Date: 2007-02-01 Impact factor: 6.860
Authors: F R Macbeth; T E Wheldon; D J Girling; R J Stephens; D Machin; N M Bleehen; A Lamont; D J Radstone; N S Reed Journal: Clin Oncol (R Coll Radiol) Date: 1996 Impact factor: 4.126
Authors: Peter C Gerszten; Steven A Burton; Annette E Quinn; Sanjiv S Agarwala; John M Kirkwood Journal: Stereotact Funct Neurosurg Date: 2006-03-08 Impact factor: 1.875
Authors: Peter S Rose; Ilya Laufer; Patrick J Boland; Andrew Hanover; Mark H Bilsky; Josh Yamada; Eric Lis Journal: J Clin Oncol Date: 2009-09-08 Impact factor: 44.544
Authors: Alissar El Chediak; Ali Shamseddine; Larry Bodgi; Jean-Pierre Obeid; Fady Geara; Youssef H Zeidan Journal: Med Oncol Date: 2017-08-21 Impact factor: 3.064
Authors: Ryan S Youland; Ann T Packard; Miran J Blanchard; Andrea L Arnett; Gregory A Wiseman; Lisa A Kottschade; Roxana S Dronca; Svetomir N Markovic; Kenneth R Olivier; Sean S Park Journal: Adv Radiat Oncol Date: 2017-02-24